Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 2, 1999, Pages 263-273

  Nichols, Ronald L ^a   Graham, Donald R ^b   Barriere, Steven L ^c   Rodgers, Anthony ^c   Wilson, Samuel E ^d   Zervos, Marcus ^e   Dunn, David L ^f   Kreter, Bruce ^c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Springfield Clinic   (United States)

^c SANOFI   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f University of Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; DALFOPRISTIN PLUS QUINUPRISTIN; OXACILLIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ERYSIPELAS; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; PRURITUS; RASH; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; TIME; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFAZOLIN; CEPHALOSPORINS; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OXACILLIN; PENICILLINS; SKIN DISEASES, BACTERIAL; VANCOMYCIN; VIRGINIAMYCIN;

EID: 0032802191     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.2.263     Document Type: Article

References (15)

1. Swartz, M. N. (1995). Cellulitis and subcutaneous tissue infections. In Principles and Practice of Infectious Diseases, 4th edn, (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 909-28. Churchill Livingstone, New York.
2. Swartz, M. N. (1995). Myositis. In Principles and Practice of Infectious Diseases, 4th edn, (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 929-35. Churchill Livingstone, New York.
3. Centers for Disease Control. (1997). Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. Morbidity and Mortality Weekly Report 46, 624-6.
4. Centers for Disease Control. ( 1997). Staphylococcus aureus with reduced susceptibility to vancomycin - United States. Morbidity and Mortality Weekly Report 46, 765-6.
5. Brumfitt, W., Hamilton-Hiller, J. M. J. & Shah, S. (1992). In-vitro activity of RP59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 29-37.
6. Leclercq, R., Nantas, L., Soussy, C. J. & Duval, J. (1992). Activity of RP59500 a new parenteral semisynthetic streptogramin against staphylococci with various mechanisms of resistance to macrolide lincosamide streptogramin antibiotics. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 67-75.
7. Appelbaum, L. C., Spangler, S. K. & Jacobs, M. R. (1993). Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin, and piperacillin/tazobactam. Journal of Antimicrobial Chemotherapy 32, 223-31.
8. Nadler, H., Dowzicky, M. J., Feger, C., Pease, M. R. & Prokocimer, P. (1999). Synercid (quinupristin/dalfopristin): a novel selective-spectrum antibiotic for the treatment of multi-drug resistant and other Gram-positive pathogens. Clinical Microbiology Newsletter (In press).
9. Calandra, G. B., Norden, C., Nelson, J. D. & Mader, J. T. (1992). Evaluation of new anti-infective drugs in the treatment of selected infections of the skin and skin structure. Clinical Infectious Diseases 15, Suppl. 1, S148-54.
10. Zelen, M. (1974). The randomization and stratification of patients to clinical trials. Journal of Chronic Diseases 27, 365-75.
11. Maki, D., Weise, C. & Sarafin, H. (1977). A semiquantitative culture method for identifying intravenous catheter-related infections. New England Journal of Medicine 296, 1305-9.
12. National Committee for Clinical Laboratory Standards. (1990). Performance Standards for Antimicrobial Disk Susceptibility Tests -Fourth Edition: Document M2-A4. NCCLS, Villanova, PA.
13. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Organisms that Grow Aerobically - Second Edition: Approved Standard M7-A2. NCCLS, Villanova, PA.
14. Tan, J. S., Wishnow, R. M., Talan, D. A., Duncanson, F. P. & Norden, C. W. (1993). Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrobial Agents and Chemotherapy 37, 1580-6.
15. Rehm, S. J., Schmitt, S. K., Gordon S. M., Adal, K. A., Mawhorter, S. D., Brakeman, J. et al. (1998). Experience with quinupristin/dalfopristin (RP59500 Synercid), administration outside the hospital. In Program and Abstracts of the Eighth International Congress of Infectious Diseases, Boston, USA, 1998. Abstract 48.022. International Society of Infectious Diseases.